Remdesivir activates urotensin II receptor and induces cardiomyocyte dysfunction

In a recent study posted to the bioRxiv* preprint server, researchers assessed the cardiac effects of remdesivir.

Study: Activation of the urotensin-II receptor by anti-COVID-19 drug remdesivir induces cardiomyocyte dysfunction. Image Credit: felipe caparros/Shutterstock
Study: Activation of the urotensin-II receptor by anti-COVID-19 drug remdesivir induces cardiomyocyte dysfunction. Image Credit: felipe caparros/Shutterstock

Background

Nucleoside analogs have been long used for designing antiviral drugs. Nucleoside analogs inhibit viral RNA-dependent RNA polymerase (RdRp). Several analogs, such as remdesivir, favipiravir, and molnupiravir, have been approved to treat coronavirus disease 2019 (COVID-19).

Remdesivir, a modified adenosine analog, is rapidly converted to a mono-nucleoside form upon intravenous administration. Subsequently, it is metabolized by host enzymes to the active triphosphate state. The active drug is a selective and potent inhibitor of RdRp of many viruses. Initially used for treating the Ebola virus, remdesivir was approved for COVID-19 amid the pandemic.

Although well tolerated by most patients, commonly reported adverse events include a rash, nausea, headache, and elevated transaminases. Moreover, cardiovascular events such as bradycardia, hypertension, T-wave abnormality, and QT prolongation have been reported.

Remdesivir distributes to multiple tissues, including the heart; however, the mechanisms underlying the cardiovascular complications remain unknown.

Molnupiravir and favipiravir have been used for COVID-19 treatment. Although different adverse events have been reported, no cardiovascular event has been reported with the use of favipiravir or molnupiravir. Nucleosides or nucleotides also act as ligands for G-protein-coupled receptors (GPCRs). As nucleoside analogs mimic structures, it is hypothesized that they could activate GPCRs and cause side effects.

The study and findings

In the present study, researchers carried out a large-scale GPCR screening using the three anti-COVID-19 drugs. The nucleoside analogs were screened against 348 GPCRs in a transforming growth factor (TGF)-α shedding assay. Initially, screening was performed using Gα subunits for efficient detection of receptor activation. The authors noted that remdesivir selectively activated the urotensin II receptor (UTS2R).

Concentration-response analysis showed a half-maximal effective concentration (pEC50) of 4.89 for remdesivir, albeit lower than that of urotensin II, the endogenous ligand of UTS2R. Intriguingly, remdesivir did not induce a β-arrestin recruitment response, unlike urotensin II, and thus was a G-protein-biased ligand. The major and minor metabolites of remdesivir, GS-441524, and GS-704277, did not affect the activation of UTS2R.

Further investigation revealed that receptor activation required both the nucleoside base and the McGuigan prodrug moiety of remdesivir. In silico structural docking of UTS2R and remdesivir identified multiple residues in the orthosteric pocket, potentially stabilizing binding to remdesivir. Three residues of UTS2R (T304, N297, and M134) were found to interact with remdesivir. Substituting these residues with others abolished the activation potency of remdesivir.

Next, HEK293 cells expressing UTS2R were stimulated with remdesivir, and the phosphorylation of extracellular signal regulation kinase (ERK) 1/2 was examined. Remdesivir treatment induced long-lasting phosphorylation of ERK1/2 in a dose-dependent manner. Remdesivir-mediated phosphorylation was abolished in the presence of a UTS2R antagonist.

The impact of remdesivir on cardiomyocytes was assessed given the high expression of UTS2R and urotensin II in cardiovascular systems. The drug’s effect was analyzed on the field potential (FP) using human-induced pluripotent stem (iPS) cell-derived cardiomyocytes, in which UTS2R levels are comparable to that of the heart.

A multielectrode assay showed that remdesivir-treated cells showed prolonged FP duration that was significantly suppressed in the presence of a UTS2R antagonist. The effects of the drug on cardiac contractility were assessed on neonatal rat cardiomyocytes (NRCMs). Chronic remdesivir application on NRCMs resulted in reduced contractility attenuated by UTS2R antagonist.

The team constructed 110 missense mutants corresponding to human single nucleotide variants (SNVs) in the UTS2R gene. Of these, 44 SNVs exhibited lower sensitivity to remdesivir relative to the wildtype receptor. In contrast, 47 SNVs had reduced sensitivity to urotensin II.

Notably, four missense SNVs increased sensitivity to remdesivir relative to wildtype. Of these, two SNVs had lower sensitivity to urotensin II, while the other two had a moderate/insignificant increase in sensitivity to urotensin II. Individuals with these mutations might be more susceptible to remdesivir/UTS2R-mediated cardiotoxicity.

Conclusions

The authors discovered that remdesivir selectively activated UTS2R. UTS2R activation by urotensin II has been implicated in cardiac dysfunction. As such, UTS2R activation by remdesivir in cultured cardiomyocytes induced electrical abnormalities and impaired contractility, resembling the reported cardiac events in humans. Notably, the adverse effects were negated by antagonizing UTS2R or blocking the downstream signaling.

The findings suggested that the clinical dose of remdesivir was adequate to trigger UTS2R activation. Notwithstanding the finding that UTS2R is activated by remdesivir leading to cardiotoxicity, a limitation of the study is the lack of clinical evidence.

In summary, the study provided mechanistic insights into remdesivir-mediated cardiac effects and discovered that it acts as a selective UTS2R agonist.

*Important notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Tarun Sai Lomte

Written by

Tarun Sai Lomte

Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sai Lomte, Tarun. (2022, August 12). Remdesivir activates urotensin II receptor and induces cardiomyocyte dysfunction. News-Medical. Retrieved on October 06, 2022 from https://www.news-medical.net/news/20220812/Remdesivir-activates-urotensin-II-receptor-and-induces-cardiomyocyte-dysfunction.aspx.

  • MLA

    Sai Lomte, Tarun. "Remdesivir activates urotensin II receptor and induces cardiomyocyte dysfunction". News-Medical. 06 October 2022. <https://www.news-medical.net/news/20220812/Remdesivir-activates-urotensin-II-receptor-and-induces-cardiomyocyte-dysfunction.aspx>.

  • Chicago

    Sai Lomte, Tarun. "Remdesivir activates urotensin II receptor and induces cardiomyocyte dysfunction". News-Medical. https://www.news-medical.net/news/20220812/Remdesivir-activates-urotensin-II-receptor-and-induces-cardiomyocyte-dysfunction.aspx. (accessed October 06, 2022).

  • Harvard

    Sai Lomte, Tarun. 2022. Remdesivir activates urotensin II receptor and induces cardiomyocyte dysfunction. News-Medical, viewed 06 October 2022, https://www.news-medical.net/news/20220812/Remdesivir-activates-urotensin-II-receptor-and-induces-cardiomyocyte-dysfunction.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Study suggests B-cell responses to booster vaccines are impeded by recent SARS-CoV-2 infection